In the Claims:

Claims 1-17 (Canceled)

New claims 18-33

18. (New) A pharmaceutical formulation comprising olanzapine or a pharmaceutically acceptable salt thereof as an active ingredient, produced by homogeneously mixing (a) olanzapinc or a pharmaceutically acceptable salt thereof with (b) a monosaccharide and/or oligosaccharide and/or a reduced or oxidised form thereof, (c) a polysaccharide and optionally one or more additional excipients, followed by a direct compression of the mixture into tablets in the absence of any solvent.

19. (New) The pharmaceutical formulation of claim 18 comprising 40 to 80 weight % of the component (b).

20. (New) The pharmaceutical formulation of claim 18 comprising 10 to 40 weight % of the polysaccharide.

21. (New) The pharmaceutical formulation of claim 18 additionally comprising (d) up to 15 weight % of a disintegrant.

22. (New) The pharmaceutical formulation claim 18 additionally comprising (e) 5 to 20 weight % of a binder.

23. (New) The pharmaceutical formulation of claim 18 additionally comprising (f) 0.25 to 5 weight % of a lubricant.

24. (New) The pharmaceutical formulation of claim 18 additionally comprising (g) 0.1 to 0.5 weight % of a glidant.

25. (New) The pharmaceutical formulation of claim 18, wherein the component (b) is selected from the group consisting of lactose, sucrose, dextrose, sorbitol, mannitol, lactitol, and mixtures thereof.

26. (New) The pharmaceutical formulation of claim 25, wherein the component (b) is lactose.

27. (New) The pharmaceutical formulation of claim 18, wherein the polysaccharide is selected from the group consisting of starch, cellulose, and mixtures thereof.

28. (New) The pharmaceutical formulation of claim 27, wherein the polysaccharide is cellulose.

29. (New) The pharmaceutical formulation of claim 28, wherein a mixture of 20 to 30 weight % of cellulose and 70 to 80 weight % of lactose is used as the components (b) and (c).

30. (New) The pharmaceutical formulation of claim 29 comprising
70 to 90 weight % of a mixture of 20 to 30 weight % of cellulose and 70 to 80

weight % of lactose;

8 to 12 weight % of a binder;

3 to 10 weight % of a disintegrant;

0.3 to 2 weight % of a lubricant; and

0.2 to 0.4 weight % of a glidant.

31. (New) The pharmaceutical formulation of claim 18 comprising olanzapinc as the only pharmaceutically active ingredient.

32. (New) The pharmaceutical formulation of claim 18 having the form of an uncoated tablet.

33. (New) A process for preparing a stable pharmaceutically solid oral formulation comprising combining (a) olanzapine or a pharmaceutically acceptable salt thereof with (b) a monosaccharide and/or oligosaccharide and/or a reduced or oxidised form thereof, (c) a polysaccharide and optionally one or more of disintegrant, binder, lubricant and glidant, followed by a direct compression of the mixture into tablets in the absence of any solvent.